A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma

NCT06261957 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

477

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: Salbutamol HFA-134a
DRUG: Salbutamol HFA-152a

Sponsor

GlaxoSmithKline